期刊名称：TRAVEL MEDICINE AND INFECTIOUS DISEASE
 期刊简介(About the journal)
投稿须知(Instructions to Authors)
编辑部信息(Editorial Board)
About the journal
The journal will publish original papers and invited reviews covering all aspects of travel medicine and infectious disease. These will include the epidemiology and surveillance of travel-related infectious disease, vaccine-preventable disease, illness in returning travellers, aviation medicine including psychological aspects, environmental hazards of travel, practical clinical issues for travellers, tropical medicine and tropical skin disease and general aspects of travel medicine and infectious disease.
The journal will also bring together knowledge from different specialties involved in the research and clinical practice of travel medicine and infectious disease.
The journal will publish topical leading academic reviews and opinion papers, original articles and case reports as well as a correspondence section.
Instructions to Authors
Manuscript Preparation
Avoid full justification, i.e., do not use a constant right-hand margin. Ensure that each new paragraph is clearly indicated. Present tables and figure legends on separate pages at the end of the manuscript. If possible, consult a recent issue of the journal to become familiar with layout and conventions. Number all pages consecutively.
Authors should note that upon submission of their manuscripts to the Editor, they must ensure that they have adhered to the following checklist:
- One author is designated as the corresponding author and provides the following information: E-mail address, Full postal address, Telephone and fax numbers,
- All text pages
- Keywords (3 - 6 words)
- Original artwork (high-quality jpgs or tiffs)
- All figure captions
- All tables (including title, description, footnotes)
A covering letter signed by all authors should accompany the manuscript, identifying the person (with the full address, telephone and fax numbers and email address) responsible for negotiations concerning the manuscript; the letter should make it clear that the final manuscript has been seen and approved by all authors.
During the submission process, authors will be asked to submit the names and contact details of up to four potential referees.
Papers should be set out as follows, with each section beginning on a separate sheet: Title Page, Abstract, Key words (3-6), Introduction, Materials and Methods, Results, Discussion, Acknowledgements, References, Tables and Figures with legends. The Editor will consider the use of other sections if more suitable for certain manuscripts.
Title page: The title page should give the following information (in the order stated):
- Title. Concise and informative, the title should be informative and not exceed 85 characters, including spaces. Titles are often used in information-retrieval systems. Avoid abbreviations and formulae where possible. Avoid use of extraneous words such as "study", "investigation", etc.
- Author names, qualifications and affiliations. Where the family name may be ambiguous (e.g., a double name), please indicate this clearly. State the authors' highest-earned degree. Present the authors' affiliation addresses (where the actual work was done) below the names. Indicate all affiliations with a lower-case superscript letter immediately after the author's name and in front of the appropriate address. Provide the full postal address of each affiliation, including the country name, and, if available, the e-mail address of each author.
- Corresponding author. Clearly indicate who is willing to handle correspondence at all stages of refereeing and publication, also post-publication. Ensure that telephone and fax numbers (with country and area code) are provided in addition to the e-mail address and the complete postal address.
- Present/permanent address. If an author has moved since the work described in the article was done, or was visiting at the time, a 'Present address' (or 'Permanent address') may be indicated as a footnote to that author's name. The address at which the author actually did the work must be retained as the main, affiliation address. Superscript Arabic numerals are used for such footnotes.
- Other information. If data from the manuscript have been presented at a meeting, list the full name, date and location of the meeting and reference any previous published abstracts in the bibliography.
Authorship should be assumed only by those who have contributed materially to the work and its report. Colleagues who have otherwise assisted or collaborated should be recognised in the Acknowledgement section.
Abstract: Original articles should include a structured abstract of no more than 200 words. In original articles, the Abstract should consist of 4 paragraphs, labelled Background, Method, Results, Conclusions. They should briefly describe the problems being addressed in the study, how the study was performed and which measurements were carried out, the most relevant results, and what the authors conclude from the results. A recent copy of the journal should be consulted as a guide. An abstract is often presented separate from the article, so it must be able to stand alone.
Keywords: Authors should provide a list of 3 - 6 keywords (not used in the title) on the first page of the manuscript, avoiding general and plural terms and multiple concepts (avoid, for example, 'and', 'of'). Use terms form the Medical Subject headings from the Index Medicus. Be sparing with abbreviations: only abbreviations firmly established in the field may be eligible. These keywords will be used for indexing purposes.
DNA sequences and GenBank Accession numbers: Many Elsevier journals cite "gene accession numbers" in their running text and footnotes. Gene accession numbers refer to genes or DNA sequences about which further information can be found in the databases at the National Center for Biotechnical Information (NCBI) at the National Library of Medicine. Elsevier authors wishing to enable other scientists to use the accession numbers cited in their papers via links to these sources, should type this information in the following manner:
For each and every accession number cited in an article, authors should type the accession number in bold, underlined text . Letters in the accession number should always be capitalised. (See Example below). This combination of letters and format will enable Elsevier's typesetters to recognise the relevant texts as accession numbers and add the required link to GenBank's sequences.
Example: "GenBank accession nos. AI631510, AI631511, AI632198, and BF223228 ), a B-cell tumor from a chronic lymphatic leukemia (GenBank accession no. BE675048 ), and a T-cell lymphoma (GenBank accession no. AA361117 )".
Authors are encouraged to check accession numbers used very carefully. An error in a letter or number can result in a dead link. In the final version of the electronic copy, the accession number text will be linked to the appropriate source in the NCBI databases enabling readers to go directly to that source from the article.
Introduction: The Introduction should be brief and set out the purposes for which the study has been performed.
Materials and Methods: The Materials and Methods should be sufficiently detailed so that readers and reviewers can understand precisely what has been done without studying the references directly. The description may be abbreviated when well accepted techniques are used.
Results: The Results should be presented precisely. Keep discussion of their importance to a minimum in this section of the manuscript.
Discussion: The Discussion should directly relate to the study being reported. Do not include a general review of the topic.
Do not use "he", "his", etc where the sex of the person is unknown; say "the patient", etc. Avoid inelegant alternatives such as "he/she". Patients should not be automatically designated as "she", and doctors as "he".
ILLUSTRATIONS
The electronic text should be prepared as done for conventional manuscripts (see also the Author's Guide to Publishing with Elsevier: www.elsevier.com/authors). Do not import the figures into the text file but, instead, indicate their approximate locations directly in the electronic text and on the manuscript. See also the section on the Preparation of electronic illustrations. Colour figures must be clearly marked as being intended for colour reproduction or to be reproduced in black-and-white. Reproduction of colour figures will incur a charge to the author; however if both colour and black-and-white figures (of the same figure) are supplied, it is possible to have the black-and-white image appear in print, and the colour image to appear on the online version at no extra cost. Please indicate if you would prefer this at the time of submission.
Patient confidentiality: Where illustrations must include recognizable individuals, living or dead or of whatever age, great care must be taken to ensure that consent for publication has been given. If identifiable features are not essential to the illustration, please indicate where the illustration can be cropped. In cases where consent has not been obtained and recognisable features may appear, it will be necessary to retouch the illustration to mask the eyes or otherwise render the individual "officially unrecognisable".
Permissions to reproduce borrowed illustrations or tables or identifiable clinical photographs: Written permission to reproduce borrowed material (illustrations and tables) must be obtained from the original publishers and authors, and submitted with the typescript. Borrowed material should be acknowledged in the captions in this style: 'Reproduced by the kind permission of . . . (publishers) from . . . (reference)'.
TABLES
When preparing tables, if you are using a table grid, use only one grid for each individual table and not a grid for each row. If no grid is used, use tabs, not spaces, to align columns.
Tables should be typed with double spacing each on a separate sheet, numbered consecutively in accordance with their appearance in the text. A short descriptive title should appear above each table and footnotes to tables are to be placed below the table body and indicate them with superscript lowercase letters. Avoid vertical rules. Be sparing in the use of tables and ensure that the data presented in tables do not duplicate results described elsewhere in the article.
REFERENCES
References should be numbered consecutively (in square brackets) as they appear in the text. Type the reference list with double spacing on a separate sheet.
Text: Indicate references by number(s) in square brackets in line with the text. The actual authors can be referred to, but the reference number(s) must always be given.
List: Number the references (numbers in square brackets) in the list in the order in which they appear in the text.
Examples:
Reference to a journal publication:
[1] Van der Geer J, Hanraads JAJ, Lupton RA. The art of writing a scientific article. J Sci Commun 2000;163:51-9.
Reference to a book:
[2] Strunk Jr W, White EB. The elements of style. 3rd ed. New York: Macmillan; 1979.
Reference to a chapter in an edited book:
[3] Mettam GR, Adams LB. How to prepare an electronic version of your article. In: Jones BS, Smith RZ, editors. Introduction to the electronic age, New York: E-Publishing Inc; 1999, p. 281-304
Note shortened form for last page number. e.g., 51-9, and that for more than 6 authors the first 6 should be listed followed by 'et al.' For further details you are referred to "Uniform Requirements for Manuscripts submitted to Biomedical Journals" (J Am Med Assoc 1997;277:927-934) (see also http://www.nejm.org/general/text/requirements/1.htm) Please note that all authors should be listed when six or less; when seven or more, list only the first three and add et al. Do not list references to personal communications, unpublished data or manuscripts either in preparation or submitted for publication. If essential, such material may be incorporated into the appropriate place in the text. Recheck references in the text against reference list after your manuscript has been revised.
Digital Object Identifier
Elsevier assigns a unique digital object identifier (DOI) to every article it publishes. The DOI appears on the title page of the article. It is assigned after the article has been accepted for publication and persists throughout the lifetime of the article. Due to its persistence, it can be used to query Elsevier for information on the article during the production process, to find the article on the Internet through various Web sites, including ScienceDirect, and to cite the article in academic references. When using an Elsevier article in a reference section, it is important to include the article's DOI in the reference as volume and page information is not always available for articles published online. The References section shows samples of DOI included in references.
Brief reports
Brief reports containing concise reports on original work will be considered for publication. Case Reports which are relevant for understanding the pathophysiology or clinical presentation of Infectious Disease may also be accepted under this heading. Articles published in this section should preferably be no more than 2,000 words, 3-6 key words, preferably be no more than 2 figures and /or tables, and references.
Correspondence
Correspondence may be submitted to the journal in the form of Letters to the Editor or short papers of no more than 500 words. Tables, figures and references should be kept to a minimum.
Book Reviews
Submission of book reviews of up to 450 words may be submitted to the Editor along the same route as normal manuscripts. Books for reviews may also be sent to the Editor at the address given above.
Abbreviations
Measurements should be abbreviated according to SI units. All other abbreviations or acronyms should be defined on first appearance in the text. Use a capital letter for proprietary names of substances and materials. At first mention of a chemical substance, use the correct chemical designation as well as the generic name.
Policy and Ethics
Work on human beings that is submitted to Travel Medicine and Infectious Diseases should comply with the principles laid down in the Declaration of Helsinki; Recommendations guiding physicians in biomedical research involving human subjects. Adopted by the 18th World Medical Assembly, Helsinki, Finland, June 1964, amended by the 29th World Medical Assembly, Tokyo, Japan, October 1975, the 35th World Medical Assembly, Venice, Italy, October 1983, and the 41st World Medical Assembly, Hong Kong, September 1989. The manuscript should contain a statement that the work has been approved by the appropriate ethical committees related to the institution(s) in which it was performed and that subjects gave informed consent to the work. Studies involving experiments with animals must state that their care was in accordance with institution guidelines.
Studies on patients or volunteers require ethics committee approval and informed consent which should be documented in your paper. Patients have a right to privacy. Therefore identifying information, including patients' images, names, initials, or hospital numbers, should not be included in videos, recordings, written descriptions, photographs, and pedigrees unless the information is essential for scientific purposes and you have obtained written informed consent for publication in print and electronic form from the patient (or parent, guardian or next of kin where applicable). If such consent is made subject to any conditions, Elsevier must be made aware of all such conditions. Written consents must be provided to Elsevier on request. Even where consent has been given, identifying details should be omitted if they are not essential. If identifying characteristics are altered to protect anonymity, such as in genetic pedigrees, authors should provide assurance that alterations do not distort scientific meaning and editors should so note. If such consent has not been obtained, personal details of patients included in any part of the paper and in any supplementary materials (including all illustrations and videos) must be removed before submission.
Further guidance on relevant ethical principles are available from the Nuffield Council on Bioethics http://www.nuffieldbioethics.org/publications/index.asp
Work involving animals must have been carried out in accordance with EC Directive 86/609/ECC for animal experiments; http://europa.eu.int/scadplus/leg/en/s23000.htm.
Randomised controlled trials
All randomised controlled trials submitted for publication in TMAID should include a completed Consolidated Standards of Reporting Trials (CONSORT) flow chart. Please refer to the CONSORT statement website at http://www.consort-statement.org for more information. TMAID has adopted the proposal from the International Committee of Medical Journal Editors (ICMJE) which require, as a condition of consideration for publication of clinical trials, registration in a public trials registry. Trials must register at or before the onset of patient enrolment. The clinical trial registration number should be included at the end of the abstract of the article. For this purpose, a clinical trial is defined as any research project that prospectively assigns human subjects to intervention or comparison groups to study the cause-and-effect relationship between a medical intervention and a health outcome. Studies designed for other purposes, such as to study pharmacokinetics or major toxicity (e.g. phase I trials) would be exempt. Further information can be found at www.icmje.org.revisions received later than 3 months after this request will be treated as new submissions.
Acknowledgements
All contributors who do not meet the criteria for authorship as defined above should be listed in an acknowledgements section. Examples of those who might be acknowledged include a person who provided purely technical help, writing assistance, or a department chair who provided only general support. Authors should disclose whether they had any writing assistance and identify the entity that paid for this assistance.
Role of the funding source All sources of funding should be declared as an acknowledgement at the end of the text. Authors should declare the role of study sponsors, if any, in the study design, in the collection, analysis and interpretation of data; in the writing of the manuscript; and in the decision to submit the manuscript for publication. If the study sponsors had no such involvement, the authors should so state.
Proofs
Proofs will be sent to the authors to be carefully checked for printer's errors. Changes or additions to the edited manuscript cannot be allowed at this stage. Corrected proofs should be returned to the publisher within 2 days of receipt.
Editorial Board
Editor-in-Chief:
J. Zuckerman
Academic Centre for Travel Medicine and Vaccines, WHO Collaborating Centre for Travel Medicine, R.F.U.C.M.S., Royal Free Campus, Rowland Hill Street, London NW3 2PF, UK;, Email: tmid@.ucl.ac.uk
Deputy Editors:
E. Andersen
NHS Greater Glasgow and Clyde, Scotland
S. Toovey
Academic Centre for Travel Medicine and Vaccines, WHO Collaborating Centre for Travel Medicine, London, UK;
Editorial Board:
J.R. Alves
Institute for Infectiour Diseases Emilio Ribas, São Paulo, Brazil
S. Anderson
Stanford University School of Medicine, Stanford, USA
B. Bannister
Royal Free Hospital, London, UK
I.L. Bauer
James Cook University, Townsville, Australia
F. Bia
Yale University, New Haven, USA
T. Carter
Department for Transport, Local Government & the Regions, London, UK
I. Dale Carroll
The Travel Doctor, MI, USA
D. Durrheim
James Cook University, Townsville, Australia
C. Ellis
Heart of England NHS Foundation Trust, Birmingham, UK
V. Field
National Travel Health Network and Centre (NaTHNaC), London, UK
P.R. Fischer
Mayo Clinic, Rochester, USA
G. Flaherty
National University of Ireland, Galway, Ireland
D. Goldberg
Health Protection Scotland, Glasgow, UK
A. Green
Royal Centre for Defence Medicine, Birmingham, UK
R. Grenfell
Lister House Medical Clinic, Victoria, Australia
T.W. Heggie
Bowling Green State University, Ohio, USA
C. Herzog
Berna Biotech Ltd, Berne, Switzerland
T. Jelinek
Berlin Centre for Travel and Tropical Medicine, Germany
M. E. Jones
Western General Hospital, Edinburgh, UK
P. Leggat
James Cook University, Queensland, Australia
S. Lloveras
University of Buenos Aires, Buenos Aires, Argentina
K. Marienau
Centre for Disease Control and Prevention, Atlanta, GA, USA
A. J. Rodriguez-Morales
Universidad Central de Venezuela, Caracas, Venezuela
C. Sanford
University of Washington, Seattle, USA
M. Shaw
Worldwise Travellers Health Centres, Auckland, New Zealand
K. Smith
Health Protection Scotland, Glasgow, Scotland
K. Suh
Ottawa Hospital. Ottawa, Canada
N. Zwar
University of New South Wales, Sydney Australia
|
刊名字顺( Alphabetical List of Journals):
返回页首 